Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Sanofi SA News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
personal-finance
Can you achieve global diversification with multinational companies?
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,815.30 | 5.00 | -0.06% |
CAC 40 | 7,793.94 | 35.35 | -0.45% |
DAX 40 | 24,018.80 | 236.51 | -0.98% |
Dow JONES (US) | 44,371.51 | 279.13 | -0.63% |
FTSE 100 | 8,975.78 | 34.66 | 0.39% |
HKSE | 24,203.32 | 63.75 | 0.26% |
NASDAQ | 20,585.53 | 45.14 | -0.22% |
Nikkei 225 | 39,459.62 | 110.06 | -0.28% |
NZX 50 Index | 12,678.69 | 7.99 | -0.06% |
S&P 500 | 6,259.75 | 20.71 | -0.33% |
S&P/ASX 200 | 8,570.40 | 9.70 | -0.11% |
SSE Composite Index | 3,519.65 | 9.47 | 0.27% |